Avadel Pharmaceuticals Advances Idiopathic Hypersomnia Treatment

Avadel Pharmaceuticals (AVDL) has shared an update.

Avadel Pharmaceuticals has initiated the Phase 3 REVITALYZ trial, administering the first dose of LUMRYZ, an extended-release oral suspension aimed at treating idiopathic hypersomnia. The trial is a rigorous, placebo-controlled study designed to assess the treatment’s efficacy and safety when taken at bedtime. This marks a significant milestone in the company’s efforts to address this sleep disorder.

See more data about AVDL stock on TipRanks’ Stock Analysis page.